Here’s a question for consideration: What does it mean to acquire a virtual, single asset biotech that was ‘built’ for the sole purpose of being bought? The answer is much more complex than you might think.
Biotech fills the news these days – whether it’s the announcement of exciting new clinical data, another high-flying IPO, or a big M&A deal. Amidst the significant “share of voice” in the coverage of young and emerging biotech in the media, it’s easy to forget the relative scale of the sector relative to larger BioPharma companies.
I am a scientist by vocation and training and an entrepreneur by accident. I got into the business of starting companies when I decided almost a decade ago that I wanted to work on a new crazy therapeutic modality and the only way to do it, and innovate, was by starting from scratch; roll up your sleeves, license the IP, get VC money, build a team, and go for it. Luckily, when I co-founded my first startup company, I did not know anything about the process, so no pre-conceived biases informed by experience, sort of like skydiving and having absolute confidence your parachute will open, right? Nine years later, in my second company, I’ve learned some valuable lessons…
This blog was written by Rosana Kapeller, CSO of Nimbus Therapeutics, as part of the “From the Trenches” feature of LifeSciVC.
Venture capital investing in biotech has long been hard to disaggregate: how much goes to “early stage” vs “late stage”, how much goes to CNS vs oncology, discovery vs Phase 3, etc…
Today BIO’s David Thomas and Chad Wessel have put some much-needed light onto the biotech investor trends over the past decade with a newly released report.
Similar to this time last year, when IPOs were capturing everyone’s attention, M&A in biotech has been delivering real value. This morning HBM Partners released their outstanding report on BioPharma M&A in 2014 (here), and the conclusions are in line with the positive cadence and tenor of today’s excitement in the biotech market.